Effectiveness of Electric Stimulation Therapy in Raynaud's Phenomenon

November 6, 2020 updated by: Encarnación Aguilar Ferrandiz, Universidad de Granada

Effectiveness of an Intervention Program With Electric Stimulation Therapy in Patients With Raynaud's Phenomenon: a Randomized Clinical Trial

The purpose of this study is to analyze the effects of an intervention with galvanic electrical current on the number of attacks , temperature, pain, peripheral blow flow and upper limb functionality in patients with Raynaud's Phenomenon in comparison to a control group that will maintain their habitual treatment.

Study Overview

Detailed Description

Raynaud's Phenomenon is a disorder that causes pain and functional limitation in people who suffer it.

Investigators considerer that the application of an electrotherapy intervention with galvanic current, thanks to its vasodilator action, will produce clinically significant improvements in the number of attacks, temperature and blood flow of patients with Raynaud's Phenomenon, which can lead to a decrease in pain associated, frequency and severity of ischemic attacks and therefore an improvement in the functionality of the upper limbs.

The experimental group will receive an electrotherapy treatment using galvanic current. To apply the treatment, we will place the patient seated, with their hands inside two containers filled with water up to the limit of their nails without touching them. Next we will connect the electrodes and apply a galvanic current for 10 minutes, there will be a minute of rest for the patient while we change the polarity of this current and we will apply it another 10 minutes. The intensity of the current depends on the threshold of the patient.

The control group will maintain their usual conservative and pharmacological treatment without receiving electrotherapy

Study Type

Interventional

Enrollment (Actual)

60

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Granada, Spain, 18001
        • University of Granada

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Being over 18 years of age.
  • Being diagnosed with Primary or Secondary Raynaud Phenomenon according to the criteria established by LeRoy-Medsger.
  • A history of at least one year of regular attacks of pallor or acral cyanosis caused by exposure to cold and/or stress.
  • Having signed the informed consent document and willingness to participate in the study

Exclusion Criteria:

  • Presence of skin alterations such as stings, scars, ulcers or gangrene in the examined area.
  • Suffering upper limb entrapment syndrome, central nervous system polyneuropathy, Hypothyroidism, renal failure, cerebral or cardiac ischemic disease.
  • History of drug or alcohol abuse.
  • Pregnant or breastfeeding women.
  • Use of vibratory tools.
  • Participants with tumour process.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Electric Stimulation Therapy Group
The experimental group will receive an electrotherapy treatment with galvanic current in their hands. Electrotherapy with galvanic current has vasodilator action.
The experimental group will receive an electrotherapy treatment with galvanic current in their hands.This protocol will be administered at weekly sessions of 30 minutes with a period of 3 times / week with a total of 20 sessions, distributed over a 7-week period. They will be evaluated at baseline, after the end of the last treatment session and after two months of follow-up.
Other Names:
  • Electric Stimulation Therapy
Active Comparator: Control Group
The control group will be subjected to a conservative treatment. These patients will continue to take their usual medication and will not receive electrotherapy treatment
The control group continue with their usual conservative and pharmacological treatment and will not receive electrotherapy treatment. They will be evaluated too at baseline, after the end of the last treatment session and after two months of follow-up.
Other Names:
  • Control Group

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of Raynaud´s Phenomenon attacks
Time Frame: Seven Weeks
Change from baseline at the Number of Raynaud´s Phenomenon attacks
Seven Weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Temperature in the affected areas in patients with Raynaud´s Disease
Time Frame: Seven weeks
Change from baseline temperature in the infrared thermography in patients with Raynaud´s Disease
Seven weeks
Temperature in the affected areas in patients with Raynaud´s Disease
Time Frame: Fifteen weeks
Change from baseline temperature in the infrared thermography in patients with Raynaud´s Disease
Fifteen weeks
Temperature in the Cold Stress Test
Time Frame: Seven weeks
Change from temperature in the Cold Stress Test
Seven weeks
Temperature in the Cold Stress Test
Time Frame: Fifteen weeks
Change from temperature in the Cold Stress Test
Fifteen weeks
Pain Intensity: Visual Analog Scale
Time Frame: Seven weeks
Change from baseline in pain in the Visual Analog Scale. Score range between 0-10 cm where 0 is in considerer no pain and 10 is the worst pain imaginable.
Seven weeks
Pain Intensity: Visual Analog Scale
Time Frame: Fifteen weeks
Change from baseline in pain in the Visual Analog Scale. Score range between 0-10 cm where 0 is in considerer no pain and 10 is the worst pain imaginable.
Fifteen weeks
Central Sensitization
Time Frame: Seven weeks
Change from baseline in the Central Sensitization Inventory. The cumulative score ranges from 0 to 100.Higher scores indicate increased frequency and severity of the symptoms.
Seven weeks
Central Sensitization
Time Frame: Fifteen weeks
Change from baseline in the Central Sensitization Inventory. The cumulative score ranges from 0 to 100.Higher scores indicate increased frequency and severity of the symptoms.
Fifteen weeks
Pain Catastrophizing
Time Frame: Seven weeks
Change from baseline in the Pain Catastrophizing Scale. Score range is from 0 to 52; higher scores indicate a greater frequency of catastrophic thoughts.
Seven weeks
Pain Catastrophizing
Time Frame: Fifteen weeks
Change from baseline in the Pain Catastrophizing Scale. Score range is from 0 to 52; higher scores indicate a greater frequency of catastrophic thoughts.
Fifteen weeks
Oxygen Saturation
Time Frame: Seven weeks
Change from baseline in Oxygen Saturation
Seven weeks
Oxygen Saturation
Time Frame: Fifteen weeks
Change from baseline in Oxygen Saturation
Fifteen weeks
Arterial blood flow
Time Frame: Seven weeks
Change from baseline in Arterial blood flow in the radial and ulnar artery
Seven weeks
Arterial blood flow
Time Frame: Fifteen weeks
Change from baseline in Arterial blood flow in the radial and ulnar artery
Fifteen weeks
Upper limb disability
Time Frame: Seven Weeks
Change from baseline in the Disabilities of the Arm, Shoulder and Hand Questionnaire. The score ranges from 0 (no disability) to 100 (most severe disability). Higher scores indicate a greater level of disability and severity.
Seven Weeks
Upper limb disability
Time Frame: Fifteen Weeks
Change from baseline in the Disabilities of the Arm, Shoulder and Hand Questionnaire. The score ranges from 0 (no disability) to 100 (most severe disability). Higher scores indicate a greater level of disability and severity.
Fifteen Weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Mª Encarnación ME Aguilar Ferrándiz, PhD, Universidad de Granada

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 1, 2018

Primary Completion (Actual)

December 1, 2018

Study Completion (Actual)

February 20, 2019

Study Registration Dates

First Submitted

October 4, 2018

First Submitted That Met QC Criteria

October 5, 2018

First Posted (Actual)

October 9, 2018

Study Record Updates

Last Update Posted (Actual)

November 9, 2020

Last Update Submitted That Met QC Criteria

November 6, 2020

Last Verified

November 1, 2020

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Raynaud Disease

Clinical Trials on Electrotherapy with Galvanic Current

3
Subscribe